中國旭陽(01907.HK)氨基醇產品通過歐美REACH認證
中國旭陽(01907.HK)公布,集團氨基醇產品於2025年7月18日成功通過歐盟REACH註冊,正式獲得歐盟市場通行證,標誌著集團的氨基醇已具備覆蓋出口歐盟的法定註冊額度。
歐盟REACH法規全稱為「化學品的註冊、評估、授權和限制」(Registration, Evaluation, Authorisation and Restriction of Chemicals),是歐盟對境內流通化學品實施強制性管理的核心制度,要求企業必須對化學品的生產、使用及潛在風險進行全面評估,並提交詳盡的數據報告,其中當年進出口量超過1噸時必須向歐盟化學品管理局(ECHA)完成正式註冊,否則禁止進入歐盟市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.